No effects of a 6‐week intervention with a glucagon‐like peptide‐1 receptor agonist on pancreatic volume and oedema in obese men without diabetes-Reference-Cited by-同舟云学术

No effects of a 6‐week intervention with a glucagon‐like peptide‐1 receptor agonist on pancreatic volume and oedema in obese men without diabetes

Published:2020-07 Issue:10 Volume:22 Page:1837-1846
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Svane Maria S.¹²,Johannesen Helle H.³,Martinussen Christoffer¹²,Bojsen‐Møller Kirstine N.¹²,Hansen Martin Lundsgaard⁴,Hansen Adam E.³,Deacon Carolyn F.²⁵^ORCID,Hartmann Bolette²⁵,Keller Sune H.³,Klausen Thomas L.³,Loft Annika³,Kjaer Andreas³⁵,Madsbad Sten¹,Löfgren Johan³,Holst Jens J.²⁵,Wewer Albrechtsen Nicolai J.⁵⁶^ORCID

Affiliation:

1. Department of Endocrinology Hvidovre Hospital Hvidovre Denmark

2. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

3. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet University of Copenhagen Copenhagen Denmark

4. Department of Radiology, Rigshospitalet University of Copenhagen Copenhagen Denmark

5. Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

6. Department of Clinical Biochemistry, Rigshospitalet University of Copenhagen Copenhagen Denmark

Funder

Rigshospitalet

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14106

Reference30 articles.

1. Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications

2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

4. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

5. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Pharmacological Landscape for Fatty Change of the Pancreas;Drugs;2024-04

2. Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy;iScience;2023-11

3. Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications;Cardiovascular Endocrinology and Metabolism;2023

4. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight;International Journal of Obesity;2022-08-18

5. Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?;Journal of Internal Medicine;2022-01-24